2012
Memantine, an NMDA receptor antagonist, differentially influences Go/No-Go performance and fMRI activity in individuals with and without a family history of alcoholism
Jamadar S, DeVito EE, Jiantonio RE, Meda SA, Stevens MC, Potenza MN, Krystal JH, Pearlson GD. Memantine, an NMDA receptor antagonist, differentially influences Go/No-Go performance and fMRI activity in individuals with and without a family history of alcoholism. Psychopharmacology 2012, 222: 129-140. PMID: 22311382, PMCID: PMC3674025, DOI: 10.1007/s00213-011-2628-2.Peer-Reviewed Original ResearchConceptsNMDA receptor antagonistFamily historyFHN subjectsReceptor antagonistFHP subjectsN-methyl-D-aspartate receptor functionReceptor functionIdentical-appearing placeboEffects of memantineFMRI activityNMDA receptor functionCorrect rejectsSingle doseMemantineGo/No-Go taskSeparate daysTemporal regionsCingulate activation
2001
Quantitative Morphology of the Caudate and Putamen in Patients With Cocaine Dependence
Jacobsen LK, Giedd JN, Gottschalk C, Kosten TR, Krystal JH. Quantitative Morphology of the Caudate and Putamen in Patients With Cocaine Dependence. American Journal Of Psychiatry 2001, 158: 486-489. PMID: 11229995, DOI: 10.1176/appi.ajp.158.3.486.Peer-Reviewed Original ResearchConceptsCocaine dependenceDopaminergic functionStriatal dopaminergic depletionTypical neuroleptic treatmentTotal brain volumeChronic cocaine dependenceCocaine-dependent subjectsChronic cocaine useStriatal hypertrophyExtrapyramidal symptomsNeuroleptic treatmentDopaminergic depletionHealthy subjectsBrain volumePutamen volumeCocaine useStriatal structuresCaudatePatientsPutamenHypertrophyMagnetic resonanceDeficitsQuantitative morphologySubjects